RPA1 and lung carcinoma: • 43/NERx-329 shows degradation of replication forks upon stalling and RPA exhaustion, single agent activity in a broad spectrum of cancer cells and synergism with cisplatin, etoposide, bleomycin, BMN673, NU7441 and VE821 in lung cancer cells. IC50 = 3-10 μM